<- Go Home
Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Market Cap
$78.7M
Volume
953.7K
Cash and Equivalents
N/A
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$5.50
52 Week Low
$1.54
Dividend
N/A
Price / Book Value
-18.53
Price / Earnings
-1.03
Price / Tangible Book Value
-18.53
Enterprise Value
$60.0M
Enterprise Value / EBITDA
N/A
Operating Income
N/A
Return on Equity
703.68%
Return on Assets
-142.36
Cash and Short Term Investments
N/A
Debt
N/A
Equity
N/A
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A